我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

IL-1β、IL-6对人冠脉平滑肌细胞表达基质金属蛋白酶-3及基质金属蛋白酶组织抑制剂-1的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第4期
页码:
381-384
栏目:
基础研究
出版日期:
2008-08-20

文章信息/Info

Title:
Influence of interleukin-1β, interleukin-6 on matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 mRNA expression in human coronary artery smooth muscle cells
作者:
夏爱祥1; 张清华1; 蒋知新1; 方效民1; 林虎1; 王芳2; 柳扬2
解放军第305医院: 1.老年病中心，2.心内科,北京 100017
Author(s):
XIA Aixiang1;  ZHANG Qinghua1;  JIANG Zhixin1;  FANG Xiaomin1;  LIN Hu1;  WANG Fang2;  LIU Yang2
1.Center of Senile Diseases, 2.Department of Cardiology, PLA 305 Hospital, Beijing 100017, China
关键词:
急性冠脉综合征; 白细胞介素-1β; 白细胞介素-6; 基质金属蛋白酶-3; 基质金属蛋白酶组织抑制剂-1; 炎症; 实时荧光定量聚合酶链反应
Keywords:
acute coronary syndrome; interleukin1β;  interleukin6;  matrix metalloproteinase3;  tissue inhibitor of metalloproteinase1;  inflammation;  realtime fluorescent quantitation PCR
分类号:
R392.2
DOI:
-
文献标识码:
A
摘要:
目的 研究炎症因子白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）对人冠脉平滑肌细胞表达基质金属蛋白酶-3（MMP-3）和基质金属蛋白酶组织抑制剂-1（TIMP-1）的影响。方法①应用20 μg/L的IL-1β、10 μg/L的IL-6刺激人冠脉平滑肌细胞，分别在共同培养0、2、4、8、24、36 h后收集细胞。②应用不同浓度的IL-1β（0、5、20、40 μg/L）、IL-6（0、5、10、50 μg/L）刺激人冠脉平滑肌细胞，共同培养6 h后收集细胞。③应用实时荧光定量PCR的方法检测细胞内MMP-3和TIMMP-1基因的表达量。结果同剂量IL-1β、IL-6刺激下， MMP-3的表达量在2 h时就开始上调，8 h达高峰，而后开始下降；在不同剂量IL-1β、IL-6刺激下，MMP-3的表达量在实验剂量范围内随着IL-1β、IL-6的剂量加大呈上升趋势(IL-1β: r=0907，P=0000；IL6:r=0919，P=0000)。而TIMP-1表达量在2 h时就开始下调，IL-1β刺激下在8 h左右达最低，IL-6刺激下在4 h左右达最低，而后开始上升；在不同剂量IL-1β、IL-6刺激下，TIMP-1的表达量在实验剂量范围内随着IL-1β、IL-6的剂量加大呈下降趋势(IL-1β:r=-0768，P=0004;IL6:r=-0799，P=0002)。结论炎症因子IL-1β、IL-6对冠脉平滑肌细胞中斑块稳定相关标记物MMP-3、TIMP-1表达的影响，可能是炎症在急性冠脉综合征的发生发展中起非常重要作用的机制之一。
Abstract:
AIM To study the effect of interleukin1β and interleukin6 on matrix metalloproteinase3 and tissue inhibitor of metalloproteinase1 mRNA expression in human coronary artery smooth muscle cells. METHODS Human coronary artery smooth muscle cells were stimulated with interleukin1β (20 μg/L) or interleukin6 (10 μg/L). Total RNA was isolated and culture media were collected after 0, 2, 4, 8, 24 and 36 h. Human coronary artery smooth muscle cells were stimulated respectively with interleukin1β (0, 5, 20, 40 μg/L) or interleukin6（0, 5, 10, 50 μg/L）. Total RNA was isolated and culture media were collected after 6h. Realtime PCR was performed on total RNA to detect mRNA expression. RESULTS With the same concentration of interleukin1β and interleukin6, matrix metalloproteinase3 mRNA expression was upregulated at 2 hours and at 8 hours the expression reached the peak and then began to descend. With different concentrations of interleukin1β and interleukin6, matrix metalloproteinase3 mRNA expression was upregulated with the increasing dose of interleukin1β and interleukin6 (IL1β: r=0907, P=0000; IL6: r=0919, P=0000). With the same concentration of interleukin1β and interleukin6, tissue inhibitor of metalloproteinase1 mRNA expression was downregulated at 2 hours and the mRNA expression fell to the lowest at 8 hours and 4 hours in interleukin1β and interleukin6 respectively, and then began to increase. With different concentrations of interleukin1β and interleukin6, tissue inhibitor of metalloproteinase1 mRNA expression was downregulated with the increasing dose of interleukin1β and interleukin6 (IL1β: r=-0768, P=0004; IL6: r=-0799, P=0002). CONCLUSION Interleukin1β and interleukin6 promote matrix metalloproteinase3 mRNA expression and inhibit tissue inhibitor of metalloproteinase1 mRNA expression in human coronary artery smooth muscle cells, which may be one of the mechanisms of inflammation effect in acute coronary syndrome.

参考文献/References

［1］ Li J, Zhao SP, Peng DQ, et al. Changes and relations of soluble plasma CD40L and matrix metalloproteinase9 levels in patients with coronary heart disease［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2004, 29(5):517-520.

［2］ 殷忠，李兰荪，张荣庆，等. 急性冠脉综合征患者外周血MMP9及CRP的变化及其临床意义\[J\]. 心脏杂志， 2006, 18(3)：318-319,322.

［3］ Fitzsimmons PJ, Forough R, Lawrence ME, et al. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease［J］. Atherosclerosis, 2007, 194(1):196-203.

［4］ Furuholm J, Sorsa T, Qvarnstrom M, et al. Salivary matrix metalloproteinase8 in patients with and without coronary heart disease may indicate an increased susceptibility to periodontal disease［J］. J Periodontal Res, 2006, 41(5):486-489.

［5］ 单岩,徐析,单菲. 血清MMP2、MMP9水平对急性冠脉综合征的诊断及预后判断价值\[J\]. 第三军医大学学报， 2005， 27（18）：1909.

［6］ Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase9 and 2 in patients with symptomatic coronary artery disease［J］. Intern Med J, 2005, 35(6):331-335.

［7］ Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase9 and tissue inhibitor of metalloproteinase1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the AngloScandinavian Cardiac Outcomes Trial (ASCOT)［J］. Am J Hypertens, 2004, 17(9):764-769.

［8］ 李海鹰,张怀勤,季亢挺，等. 复方丹参滴丸对血管成形术后再狭窄中MMP2和MMP9的实验研究\[J\]. 心脏杂志， 2006, 18(1)：94.

［9］ 张涛，郝玉明. 基质金属蛋白酶与冠心病［J］. 临床内科杂志， 2005， 22（1）：13-15.

［10］刘丹，张清华，蒋知新，等. 冠状动脉粥样硬化斑块稳定性与超敏C反应蛋白和妊娠相关血浆蛋白A及基质金属蛋白酶组织因子抑制剂1表达的关系［J］. 中国临床康复， 2005， 9（19）：17-19.

备注/Memo

备注/Memo:
收稿日期：2007-02-01.基金项目：全军医药卫生“十五”计划重点课题（04LX048）；全军医药卫生“十一五”计划科技攻关课题（06G144） 通讯作者：夏爱祥，主治医师，硕士，主要从事炎症与急性冠脉综合征的研究Email：xprodigal@163.com
更新日期/Last Update: